Newcastle disease virus vectored avian vaccines
AssigneeMerial Limited
InventorsMichel Bublot, Frederic REYNARD, François-Xavier LE GROS
Life of this patent
Estimating the term…
Abstract
The present invention encompasses engineered Newcastle Disease Virus (NDV) vaccines or compositions. The vaccine or composition may be a recombinant vaccine. The invention also encompasses recombinant vectors encoding and expressing avian pathogen antigens, more specifically avian influenza proteins, epitopes or immunogens. Such vaccines or compositions can be used to protect animals, in particular avian, against disease.
Claims18
1-24. (canceled)
A method for modifying the genome of NDV to produce engineered NDV vector, wherein the method comprises the introduction into the NDV genome an isolated polynucleotide in a non-essential region of the NDV genome.
A method of eliciting a protective response in an avian or vaccinating an avian against at least one avian pathogen comprising administering to the avian an engineered NDV vector expressing at least one antigen and a pharmaceutically or veterinarily acceptable carrier, excipient or vehicle.
An isolated polynucleotide selected from the group consisting of:
- a) a polynucleotide having at least 90% sequence identity to a polynucleotide having the sequence as set forth in SEQ ID NO:1, 2, 4, 6, 8, 10, 12, or 24;
- b) a polynucleotide having at least 90% sequence identity to a polynucleotide encoding a polypeptide having the sequence as set forth in SEQ ID NO:3, 5, 7, 9, 11, or 13;
- and
- c) a polynucleotide complementary to the polynucleotide of a) or b).
Dependencies are inferred from the claim text.